Carlo Laudanna, M.D., Ph.D.

  • Co-Founder, Leuvas Therapeutics
  • Professor of Pathology and Immunology, University of Verona
  • Co-Founder, VENETO Pharma, Italy

Prof.  Laudanna is a pioneer and leader in the field of signal transduction and leukocyte trafficking regulation. He has made seminal contributions to the elucidation of molecular mechanisms controlling cell trafficking in normal and neoplastic leukocytes. To study the regulation of signaling mechanism in primary cells he developed several technologies, including a patented trojan peptide-based approach allowing modulation of signaling molecules in primary cells without the need of transfection. By exploiting this technology, Prof. Laudanna’s group recently unveiled the previously unappreciated role for protein tyrosine receptor phosphatase, type gamma (PTPRG) in human monocyte integrin activation and adhesion by chemoattractants. Beside the relevance to leukocyte trafficking and immune system regulation, this discovery importantly impacts the field of  signal transdcution since it provides  a new paradigm of regulation of kinome based on selective activation of protein phosphatases by means of specifically designed biological compounds. Moreover, the study clearly indicates that PTPRG is a druggable target for modulation  of tyrosine phosphorylation profiles in normal and cancer cells. In this context, two new CPPs capable of specifically upregulating the tyrosine phosphatase activity of PTPRG are described. These CPPs are the first example of compounds  allowing specific upmodulation of tyrosine phosphataes activity.

Prof. Laudanna received his M.D. and Ph.D. from the University of Verona. He is full Professor of Pathology and Immunology at the University of Verona.  Carlo was also President of the Center for Biomedical Computing and is active in the fields of bioinformatics and systems biology, with a specific focus on network inference and analysis of proteomics big data sets. He is co-founder of the biotech Veneto Pharma in Italy.

Personal website:

Selected Publications 

1:   Mirenda et al (2015) Protein tyrosine phosphatase receptor type γ is a JAK phosphatase and negatively regulates leukocyte integrin activation. J Immunol. Mar 1;194(5):2168-79.

2:   Montresor et al (2013) JAK tyrosine kinases promote hierarchical activation of Rho and Rap modules of integrin activation. J Cell Biol. Dec 23;203(6):1003-19

3:   Constantin and Laudanna (2011) Transmigration of effector T lymphocytes: changing the rules. Nat Immunol.  Dec 16;13(1):15-6.

4:   Giagulli  et al (2004) RhoA and zeta PKC control distinct modalities of LFA-1 activation by  chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. Immunity. Jan;20(1):25-35